Catalan biotech Allox raises €9.4M to advance AI drug-discovery platform
What's the deal? AlloxDealroom has a profile for this one. Try Dealroom →, a Barcelona-based biotech, has closed a €9.4 million ($10.5 million) seed round led by AsabysDealroom has a profile for this one. Try Dealroom → through its Sabadell Asabys II fund. The Centre for the Development of Industrial Technology (CDTIDealroom has a profile for this one. Try Dealroom →) and the Institut Català de Finances (ICF) also participated.
What's the endgame? A spin-off of the Centre for Genomic RegulationDealroom has a profile for this one. Try Dealroom →, Allox builds a platform to find drug targets on disease-causing proteins. It combines high-throughput biophysics with predictive AI to design small molecules aimed at historically hard-to-drug protein interactions and transcription factors.
Chief executive officer and co-founder Júlia Domingo said the technology lets the company work on "a much broader range of challenging drug targets." Allox is focused on cancer, immune-system, and inflammatory diseases, though it says the platform could extend further.
Where the money goes: The funds will scale the platform, develop AI models that predict therapeutic hotspots, and strengthen the drug-discovery team as it moves multiple programs toward a focused pipeline. Allox, based at the Barcelona Science Park, runs a 15-person team and recently doubled its lab space.
A new chair: The board appointed Morten Graugaard as independent chair. Graugaard, chief business officer at Orbis Medicines and formerly a partner at Novo HoldingsDealroom has a profile for this one. Try Dealroom →, led Lundbeck's $658 million acquisition of Chelsea Therapeutics and helped negotiate a $1.8 billion alliance with Otsuka PharmaceuticalDealroom has a profile for this one. Try Dealroom →. His arrival adds industry connections and governance as Allox enters its next development stage.
What could go wrong? Allox has not yet shown clinical or commercial validation. Its public-private backing supports expansion, but turning protein research into drug candidates is a long, uncertain path.
The signal: The round is sizeable for an early-stage drug-discovery company. It lands within a Catalan health-tech market that raised a record €517 million in 2025, with biotech accounting for €347 million — a sign that investors are still willing to back young platforms betting on AI to crack difficult drug targets.
Read more: ara.cat
Image credit: Generated with Gemini
